Clinical Trials Using Talazoparib Tosylate

Clinical trials are research studies that involve people. The clinical trials on this list are studying Talazoparib Tosylate. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-7 of 7
  • Talazoparib for the Treatment of Cohesin-Mutated Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

    This phase I trial studies how well talazoparib works in treating patients with cohesion-mutated acute myeloid leukemia that has come back (relapsed) or does not respond to treatment (refractory) or myelodysplastic syndrome. Talazoparib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
    Location: 4 locations

  • A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer

    This is two-part open label, non-randomized, Phase 2, study of ZEN003694 in combination with Talazoparib in patients with TNBC without germline mutations of BRCA1 or BRCA2. Part 1 is dose escalation and Part 2 is a Simon 2-Stage design
    Location: 4 locations

  • A Study of ZN-c3 in Participants With Solid Tumors

    This is a Phase 1 / 2 open-label, multicenter study, evaluating the safety, tolerability, efficacy, pharmacokinetics (PK) and pharmacodynamics of ZN-c3 alone and in combination with other drugs.
    Location: 2 locations

  • ASTX727 and Talazoparib for the Treatment of Triple Negative or Hormone Resistant / HER2-Negative Metastatic Breast Cancer

    This phase I trial studies the side effects and best dose of ASTX727 and talazoparib in treating patients with triple negative or hormone resistant / HER2-negative breast cancer that has spread to other places in the body (metastatic). ASTX727 is a combination of two chemotherapy drugs, cedazuridine and decitabine, and may increase the immune system's response to cancer and talazoparib. Talazoparib is an anticancer drug called a PARP (poly ADP ribose polymerase) inhibitor and is in development for the treatment of a variety of cancers. The combination of ASTX727 and talazoparib may help boost the immune system to stop or reverse the growth of tumors.
    Location: 2 locations

  • Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia

    This phase I / Ib trial studies the side effects and best dose of talazoparib given together with gemtuzumab ozogamicin and to see how well they work in treating patients with CD33 positive acute myeloid leukemia that has come back (relapsed) or does not respond to treatment (refractory). Talazoparib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Gemtuzumab ozogamicin is a protein (antibody) combined with a chemotherapy drug which specifically targets acute myeloid leukemia cells expressing a marker (CD33). Adding talazoparib to the gemtuzumab ozogamicin therapy may lead to an increased effectiveness in treatment.
    Location: Roswell Park Cancer Institute, Buffalo, New York

  • Talazoparib and Temozolomide in Treating Patients with Metastatic Castration Resistant Prostate Cancer with No Mutations in DNA Damage Repair

    This phase Ib / II trial studies the side effects and best dose of talazoparib and temozolomide and how well they work in treating patients with castration resistant prostate cancer that has spread to other places in the body (metastatic) and that does not have mutations in DNA damage repair. DNA damage repair (DDR) is a complex series of processes by which a cell identifies and fixes damage to its DNA, and DDR mutations are common in some types of cancer cells. Talazoparib is a type of medication called a PARP inhibitor. This kind of medication works by stopping cancer cells from repairing damage to themselves and their DNA, which can lead to the death of the cancer cells. Temozolomide is a chemotherapy drug that works by damaging the genetic “instructions” (DNA) in tumor cells that tell the cells to stop reproducing, which can cause them to die. Giving talazoparib and temozolomide may work better in treating patients with castration resistant prostate cancer compared to standard care.
    Location: Memorial Sloan Kettering Cancer Center, New York, New York

  • Biomarker-Driven Therapy and Immunotherapy in Screening Participants with Recurrent or Stage IV Non-Small Cell Lung Cancer (The Expanded Lung-MAP Screening Trial)

    This expansion of the screening and multi-sub-study Lung-MAP trial is motivated by the changing landscape due to progress in the development of immunotherapies. The Lung-MAP trial was originally opened in June of 2014 for second-line treatment of participants with stage IV squamous lung cancer or squamous lung cancer that has come back (recurrent). The trial was amended to allow all participants with previously-treated stage IV or recurrent squamous lung cancer in 2015. The study is now expanding to allow participants with all types of previously-treated stage IV or recurrent non-small cell lung cancer. The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned in order to compare new targeted cancer therapy designed to block the growth and spread of cancer, with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes “non-match” sub-studies which will include all screened participants not eligible for any of the biomarker-driven sub-studies.
    Location: 770 locations